A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE Smallpox Vaccine in 56-80 Year Old Vaccinia-Experienced Subjects.
Phase of Trial: Phase II
Latest Information Update: 03 Feb 2015
At a glance
- Drugs Smallpox vaccine (Primary)
- Indications Smallpox
- Focus Adverse reactions
- Sponsors Bavarian Nordic
- 23 Apr 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 09 Dec 2009 Planned end date (1 Aug 2010) added as reported by ClinicalTrials.gov
- 09 Jul 2009 Actual initiation date (1 Jun 2009) added as reported by ClinicalTrials.gov.